The pathophysiology and treatment of rhinitis medicamentosa
Authors:
- 1 June 1995
- journal article
- research article
- Published by Wiley in Clinical Otolaryngology
- Vol. 20 (3) , 224-229
Abstract
To evaluate the treatment of rhinitis medicamentosa, 10 consecutive patients discontinued their use of topical vasoconstrictors and were treated with budesonide nasal spray, 400 micrograms, daily for 6 weeks. The thickness of the nasal mucosa, the decongestive effect of oxymetazoline and the histamine sensitivity were measured with rhinostereometry. All patients were able to stop using the vasoconstrictors and objective variables showed that they needed treatment for at least 6 weeks. The results strongly support the theory that the rebound swelling is due to interstitial oedema rather than to vasodilatation. The presence of tachyphylaxis reflected by a reduction in both the decongestive effect of oxymetazoline and a reduction of drug duration was seen.Keywords
This publication has 6 references indexed in Scilit:
- Sustained Use of Xylometazoline Nose Drops Aggravates Vasomotor RhinitisAmerican Journal of Rhinology, 1991
- Intranasally administered budesonide, a glucocorticoid, does not exert its clinical effect through vasoconstrictionClinical Otolaryngology, 1989
- Variation in Nasal Mucosa Congestion during RestActa Oto-Laryngologica, 1984
- An Optical Method for Determining Changes in Mucosal Congestion in the Nose in ManActa Oto-Laryngologica, 1982
- Rhinitis medicamentosaThe Laryngoscope, 1981
- THE USE AND ABUSE OF NASAL VASOCONSTRICTOR MEDICATIONSJAMA, 1945